OpGen, Inc. (NASDAQ: OPGN) today reported financial and operating results for the three and nine months ended September 30, 2018 and provided a business update.
Total revenue for the third quarter of 2018 was $0.6 million, compared with $0.7 million for the third quarter of 2017.
Total revenue for the first nine months of 2018 was $2.2 million, consistent with the $2.2 million reported for the comparable 2017 period.
Recent business highlights include:
Â· Announcement of groundbreaking collaboration with the New York State Department of Health (DOH) and ILÃšM Health Solutions, LLC (ILÃšM), a wholly owned subsidiary of Mercks Healthcare Services and Solutions, to develop a state-of-the-art research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions statewide;
Â· Entry into collaboration with QIAGEN N.V. to advance rapid diagnostics for antimicrobial resistance based on QIAGENs EZ1 instrumentation and reagent kits in the U.S.;
Â· Completion of specimen accrual and testing in AcuitasÂ® clinical verification study with Beth Israel Deaconess Medical Center, Geisinger, and Intermountain Healthcare for initial verification of our Acuitas AMR Gene Panel tests and Acuitas Lighthouse software;
Â· Starting testing of stock bacterial isolates and analytical validation testing of IUO product to support the Acuitas AMR Gene Panel (Isolates) 510(k) FDA submission to be submitted in early 2019:
Â· Successful completion of Centers for Disease Control and Prevention (CDC) funded program for development of smartphone-based clinical decision support software with hospital testing in Colombia. Final reporting and fourth milestone payment expected during the fourth quarter of 2018;
Â· Increased installed base of Acuitas AMR Gene Panel instruments at clinical evaluation sites and commercial customers to ten systems; …
[Read on via official release]
Source: US SEC
View full document: